brexucabtagene autoleucel for Mantle Cell Lymphoma (ZUMA-2 Trial)

"At this juncture, no further enrolment is being accepted for the trial. It was first posted on November 9th 2015 and last edited May 4th 2022. Nevertheless, there are 1,720 other trials actively recruiting people with lymphoma and 894 studies seeking participants for brexucabtagene autoleucel treatments."

"In 1997, the City of Hope Comprehensive Cancer Center began researching brexucabtagene autoleucel. To this day, 1275 clinical trials have been completed and 894 studies are currently active; many of them residing in Nashville, Tennessee."

"According to the information posted on clinicaltrials.gov, this particular medical trial is no longer actively searching for participants as it was last edited on May 4th 2022. While this study has been concluded, there are 2614 other trials still open and recruiting patients."

"Brexucabtagene autoleucel is a proven therapeutic for treating lung cancers, but it also has application in multiple sclerosis and leukemia (including myelocytic acute refractory b-cell precursor acute lymphoblastic leukemia)."

"Taking into consideration the fact that brexucabtagene autoleucel is in Phase 2 trials and lacks efficacy data, its safety rating was set at a modest 2."

"The current trial encompasses 24 sites, including locations in Nashville, Tampa and Columbus. To reduce the amount of travel necessary if you join the study, it is wise to select a site nearest to your residence."